Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of ...

Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Jenna Sirkiä landed on her stomach when she fell off an e-scooter - but what doctors revealed when she went to check out her ...

The morning after the Super Bowl can be rough. Here’s how to ease your headache, nausea, and fatigue with science-backed ...

Ginger is known for its soothing effects on the stomach, and can effectively relieve nausea. It may also play a role in ...

A groundbreaking study suggests that IBS might be more of a brain issue than a gut disorder. Researchers found that stress-induced IBS symptoms could be alleviated by drugs that regulate ...

The Greenville-based treatment center has closed after the death of an 11-year-old boy the day before Thanksgiving.

State officials have shut down a residential treatment center in Hunt County three months after an 11-year-old boy cared for by the facility died in an incident that foster care officials and local ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.